http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2920080-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_277c3695533f5075b05990f25f65462f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-22
filingDate 2014-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d109acdb81b62c919ad3341b0eb9d4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41b52a1c81582dd47710afc014e4f2c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da49fd0207c4a44ad4b595f1fa6ab23f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b127525d007442de228ef74663c413c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8b11008a825a9f2b487c88a4d76fc19
publicationDate 2015-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2920080-A1
titleOfInvention A process for preparing rifaximin .kappa.
abstract The present invention relates to a process for obtaining rifaximin ? comprising the following steps:a) reacting rifamycin O with 2-amino-4-picoline in the presence of a solvent mixture comprising water and a solvent selected from methyl isobutylketone, ethylacetate and a water soluble solvent; b) obtaining a rifaximin solution by removing the aqueous phase; c) obtaining rifaximin ? from the rifaximin solution, wherein when the solvent is a water soluble solvent, either methyl isobutylketone or ethylacetate is further added in step a). In another aspect the process of the invention relates to a process for obtaining the crystalline form ? of rifaximin comprising the following steps: i) contacting rifaximin or a rifaximin solution with exclusively ethylacetate, ii) obtaining the rifaximin in crystalline form ? by removing ethylacetate.
priorityDate 2013-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559502
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57507834
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537701
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7909
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411746874
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538408
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419589390
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8857
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID180
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421014578
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280468
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423592648
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8071
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7958
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411809709
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6324616
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66824522
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554492
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426098818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1533
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490522
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6436173
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412009375

Total number of triples: 43.